A K. Ritchey
Advanced in Hemophilia A
Advanced in Hemophilia A

Overview

A. Kim Ritchey, MD, is a pediatric hematologist/oncologist and is certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics. He is vice-chair of International Affairs of the Department of Pediatrics at UPMC Children’s Hospital of Pittsburgh and is professor of pediatrics at the University of Pittsburgh School of Medicine. He received his medical degree from the University of Cincinnati School of Medicine and completed his pediatric residency at Johns Hopkins Hospital, followed by his fellowship in pediatric hematology/oncology at Yale University. Dr. Ritchey’s clinical interests include all aspects of pediatric hematology and oncology. His career focus is pediatric leukemia and coagulation disorders. He has numerous publications in peer-reviewed journals as well as book chapters and has presented both locally and nationally. He is a member of the American Society of Pediatric Hematology/Oncology where he served as president, as well as the American Society of Hematology, and the American Society of Clinical Oncology.

Dr. Ritchey is rated as an Advanced provider by MediFind in the treatment of Hemophilia A. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hemophilia B, Hemophilia A, and Leukemia.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Hemophilia A.

Specialties
Pediatric Hematology Oncology
Licenses
Specialist in PA
Board Certifications
American Board Of Pediatrics
American Board Of Pediatrics
Fellowships
Yale New Haven Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 12 Less Insurance Carriers -

Locations

UPMC Children's Hospital of Pittsburgh, Pediatric Hematology/Oncology
4401 Penn Avenue, Floor 3, Pittsburgh, PA 15224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


19 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 18 Less Clinical Trials
Similar Doctors
Frederico C. Xavier
Distinguished in Hemophilia A
Pediatric Hematology Oncology
Distinguished in Hemophilia A
Pediatric Hematology Oncology

Pediatric Hematology Oncology In Lawrenceville

4401 Penn Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English
Offers Telehealth

Frederico Xavier, MD, MS, is the associate clinical director for the Hemophilia Center of Western Pennsylvania and an associate professor of Pediatrics at the University of Pittsburgh School of Medicine. He is board-certified in Pediatrics and in Pediatric Hematology/Oncology. Dr. Xavier completed his medical degree, pediatric residency, and fellowship training in Brazil. He then completed a pediatric residency in New York, pediatric hematology and oncology fellowship at St. Jude Children’s Hospital, and then a pediatric hemostasis fellowship at the Hospital for Sick Children in Toronto, Ontario, Canada. Dr. Xavier completed a master’s degree in clinical research at the Indiana University-Purdue University Indianapolis. He has published peer-reviewed articles and book chapters in the field of pediatric hemostasis and is currently awarded with a research grant to study inflammation in Hemophilia. Dr. Xavier also sits in the Newborn Screening and Follow-up Technical Advisory Board for the Pennsylvania Department of Health. Dr. Xavier also practices at the Hemophilia Center of Western Pennsylvania, a state and federally-funded 501(c)3 charitable organization that provides comprehensive medical care to the residents of Western Pennsylvania with hemophilia and other bleeding and clotting disorders. The functions of the center include diagnosis and evaluation of individuals with bleeding disorders; treatment of bleeding episodes and complications; education of the patient and family, the community, and other medical providers; communication and advocacy; supervision of home care; and research and data collection. View the full list of Dr. Xavier’s publications on PubMed. Dr. Xavier is rated as a Distinguished provider by MediFind in the treatment of Hemophilia A. His top areas of expertise are Hemophilia A, Hemophilic Arthropathy, Hemophilia B, and Von Willebrand Disease (VWD).

James D. Cooper
Experienced in Hemophilia A
Pediatric Hematology Oncology
Experienced in Hemophilia A
Pediatric Hematology Oncology

Pediatric Hematology Oncology In Lawrenceville

4401 Penn Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English
Offers Telehealth

James Cooper, MD, MSc, is clinical director of the Coagulation Program at UPMC Children's Hospital of Pittsburgh. He is also an assistant professor of pediatrics at the University of Pittsburgh School of Medicine. He is board certified in pediatric hematology-oncology and pediatrics. Dr. Cooper earned his medical degree from University of Connecticut School of Medicine. He completed a residency and internship in pediatrics at the University of Connecticut-Connecticut Children's Medical Center followed by a fellowship in pediatric hematology-oncology at UPMC Children's Hospital. Dr. Cooper also earned his master's of science in clinical research at the University of Pittsburgh Institute for Clinical Research Education. In his role as clinical director of the Coagulation Program, Dr. Cooper cares for children with bleeding disorders and thrombosis concerns. As part of that mission, Dr. Cooper and Dr. Tahniat Syed of Adolescent Medicine co-lead a dedicated clinic for young women with menstrual disorders, known as the CHAMP (Comprehensive Hematologic Assessment of Adolescents with Menstrual Problems) Clinic. In addition to coagulation disorders, Dr. Cooper also cares for children with a variety of oncologic and other hematologic problems. Dr. Cooper’s research interests include thrombosis rates in adolescents and young adults versus younger children with cancer and the cost effectiveness of laboratory analysis of clotting disorders in children. He is a member of the American Society of Pediatric Hematology and Oncology, the American Society of Hematology, the Children’s Oncology Group, the Critical Mass Young Adult Alliance, the American Thrombosis & Hemostasis Network, the American Academy of Pediatrics, the Foundation for Women and Girls with Bleeding Disorders, and the Hemostasis and Thrombosis Research Society. View the full list of Dr. Cooper’s publications on PubMed. Dr. Cooper is rated as an Advanced provider by MediFind in the treatment of Hemophilia A. His top areas of expertise are Mesenteric Venous Thrombosis, Venous Thromboembolism (VTE), Hemophilia A, and Blood Clots.

Experienced in Hemophilia A
Pediatric Hematology Oncology
Experienced in Hemophilia A
Pediatric Hematology Oncology

University Of Pittsburgh Physicians

200 Lothrop St, Muh 4 East, 
Pittsburgh, PA 
 (1.7 miles away)
Languages Spoken:
English
Offers Telehealth

Steven Fein is a Pediatric Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Fein is rated as an Advanced provider by MediFind in the treatment of Hemophilia A. His top areas of expertise are Alpha Thalassemia, Blood Clots, Anemia, Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritchey's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile